Holen Sie sich die Stockscreener-App
5.1348
1.39%
0.1048
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
UNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 - Bluefield Daily Telegraph
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class ActionContact Levi & Korsinsky - PR Newswire
UNCY SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - GlobeNewswire
UNCY Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Unicycive Therapeutics, Inc. - Morningstar
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
Unicycive faces class action over undisclosed F... - Pluang
Deadline Soon: Unicycive Therapeutics, Inc. (UNCY) Shareholders W - The National Law Review
Bronstein, Gewirtz & Grossman LLC Urges Unicycive - GlobeNewswire
Deadline Soon: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - financialcontent.com
Class action lawsuit filed against Unicycive Th... - Pluang
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Stocktwits
UNCY Stock On Track For Worst Day In About A Year Ahead Of FDA Decision On Lead Drug - Stocktwits
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? - Stocktwits
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
UNCY INVESTOR ALERT: Securities Class Action Filed Against Unicycive Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
DEADLINE ALERT for YSS, HIMS, and UNCY: The Law Offices of - GlobeNewswire
UNCY INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Unicycive Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm - lincolnjournal.com
Law Offices of Howard G. Smith Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action - financialcontent.com
Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Securities Class Action - Business Wire
UNCY CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Unicycive Therapeutics, Inc. Investors - The Daily Tribune News
Unicycive Therapeutics stock trades near USD 5.26 - AD HOC NEWS
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - azcentral.com and The Arizona Republic
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded at Zacks Research - MarketBeat
Benchmark Co. Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Raises Target Price to $15 - Moomoo
UNCY Maintained by Benchmark -- Price Target Raised to $15.00 - GuruFocus
Benchmark raises Unicycive Therapeutics price target on FDA progress By Investing.com - Investing.com Canada
UNCY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Noble Financial Has Positive Forecast for UNCY Q3 Earnings - MarketBeat
Research Analysts Set Expectations for UNCY Q3 Earnings - MarketBeat
Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia - Bitget
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen - MarketBeat
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - TechFinancials
Nantahala Capital (UNCY) discloses 2.81M-share, 9.99% holding in Unicycive - Stock Titan
Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake - Stock Titan
Noble Financial Has Pessimistic View of UNCY Q2 Earnings - MarketBeat
B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
UNICYCIVE THERAPEUTICS INC : GUGGENHEIM CUTS TARGET PRICE TO $25 FROM $37 - webull.com
Unicycive Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.5, Implies 550% Upside - TradingView
Unicycive Therapeutics (NASDAQ:UNCY) Announces Quarterly Earnings Results - MarketBeat
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.7, Implies 554% Upside - TradingView
Unicycive Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Unicycive Therapeutics Q2 Results: EPS beats estimates by 82% - scanx.trade
Form 8K Unicycive Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Unicycive Reports Q2 2026 Results: $1.7M Net Loss, $61.4M Cash and Runway Into 2027 - TradingView
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Unicycive Reports Q2 Loss As FDA Assigns OLC Facility Inspection - Moomoo
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):